(1-fluoro-2-methylpropyl)benzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1-fluoro-2-methylpropyl)benzene
• 化学式: C₁₀H₁₃F
• 分子量: 152.212
• InChiKey: ZFAGADYCCUGUPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  异丁基苯 在 tetrakis(tetrabutylammonium)decatungstate(VI) 、 碳酸氢钠 、 N-氟代双苯磺酰胺 作用下， 以 乙腈 为溶剂， 以61%的产率得到(1-fluoro-2-methylpropyl)benzene
  参考文献：
  名称：

  N-氟苯磺酰亚胺对苄基CH键的直接光催化氟化

  摘要：

  描述了使用AIBN引发或分解钨酸盐的光催化作用，用NFSI直接将苄基CH键氟化的两种互补策略。

  DOI：

  10.1039/c5cc04058b

文献信息

• AMINO ACID COMPOUNDS AND METHODS OF USE
  申请人：Pliant Therapeutics, Inc.

  公开号：US20200109141A1

  公开（公告）日：2020-04-09

  The invention relates to compounds of formula (I): or a salt thereof, wherein R 1 , G, L 1 , L 2 , L 3 , and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, αvβ 1 integrin and αvβ 6 integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

  本发明涉及如下公式(I)的化合物： 或其盐，其中R1、G、L1、L2、L3和Y如本文所述。公式(I)的化合物及其药物组合物是αvβ1整合素和/或αvβ6整合素的一种或两种的抑制剂，用于治疗纤维化，如非酒精性脂肪肝炎（NASH）、特发性肺纤维化（IPF）和非特异性间质性肺炎（NSIP）。
• TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR
  申请人：Genentech, Inc.

  公开号：US20130217666A1

  公开（公告）日：2013-08-22

  The invention relates to novel compounds of Formula I: wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , R 2 , R 4 , R 5 , R 6 , R 7 , R 8 and subscripts m and n each has the meaning as described herein. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.

  本发明涉及公式I的新化合物：其中A1，A2，A3，A4，A5，A6，R2，R4，R5，R6，R7，R8和下标m和n的含义如此处所述。公式I的化合物及其制药组合物在治疗观察到NF-kB信号不良或过度激活的疾病和障碍方面是有用的。
• Substituted amino acids as integrin inhibitors
  申请人：Pliant Therapeutics, Inc.

  公开号：US11180494B2

  公开（公告）日：2021-11-23

  The invention relates to compounds of formula (I): or a salt thereof, wherein R1, G, L1, L2, L3, and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, αvβ1 integrin and αvβ6 integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

  本发明涉及式 (I) 化合物： 或其盐，其中 R1、G、L1、L2、L3 和 Y 如本文所述。式（I）化合物及其药物组合物是αvβ1整合素和αvβ6整合素中一种或两种的抑制剂，可用于治疗纤维化，如非酒精性脂肪性肝炎（NASH）、特发性肺纤维化（IPF）和非特异性间质性肺炎（NSIP）。
• Iron(II)-Catalyzed Benzylic Fluorination
  作者：Steven Bloom、Cody Ross Pitts、Ryan Woltornist、Andrew Griswold、Maxwell Gargiulo Holl、Thomas Lectka

  DOI：10.1021/ol400424s

  日期：2013.4.5

  Direct C-F functionalization of benzylic sp(3) C-H bonds is a synthetic challenge that has yet to be propitiously overcome. A mild, one-pot synthesis of monofluorinated benzylic substrates is reported with commercially available iron(II) acetylacetonate and Selectfluor in good to excellent yields and selectivity. A convenient route to beta-fluorinated products of 3-aryl ketones is also highlighted, providing a synthetic equivalent to the difficult to accomplish conjugate addition of fluoride to alpha,beta-unsaturated ketones.
• Dahbi, Abderrahman; Hamman, Sylvain; Beguin, Claude G., Journal of Chemical Research, Miniprint, 1989, # 5, p. 1056 - 1067
  作者：Dahbi, Abderrahman、Hamman, Sylvain、Beguin, Claude G.

  DOI：——

  日期：——